Here's what Houston organizations are benefitting from the latest CPRIT funding announcement. Photo via Getty Images

Houston’s Baylor College of Medicine is beefing up its team of cancer researchers.

The college just received $6 million from the state agency Cancer Prevention and Research Institute of Texas (CPRIT) to recruit three cancer researchers: Graham Erwin, Michael Robertson and Dr. Varun Venkataramani. Each researcher is getting $2 million.

In addition, the University of Texas MD Anderson Cancer Center snagged a $2 million CPRIT grant to recruit Simon Eschweiler.

In all, CPRIT recently announced $49 million in cancer research and prevention grants, including nearly $24 million for recruitment of cancer researchers.

Here’s a rundown of the recruitment grants awarded in Houston:

  • Graham Erwin. Erwin is a postdoctoral fellow at Stanford University’s Stanford Cancer Institute. He’s a biologist who specializes in DNA sequencing related to the development of cancer therapeutics and diagnostics.
  • Michael Robertson. Robertson also is a postdoctoral fellow at Stanford. He focuses on molecular and cellular physiology at Stanford’s medical school.
  • Dr. Varun Venkataramani. Venkataramani, a neuroscientist, is a brain tumor researcher at University Hospital Heidelberg, one of the largest hospitals in Germany.
  • Simon Eschweiler. Eschweiler is a research assistant professor at Southern California’s La Jolla Institute for Immunology. He specializes in immunotherapy for cancer patients.

Aside from the recruitment grants, three institutions in the Houston area received nearly $6 million in funding for cancer treatment and prevention programs. Here’s an overview of those grants:

  • Almost $2.5 million for expansion of a program at the University of Texas Medical Branch at Galveston that supplies HPV vaccinations for new mothers.
  • Nearly $2.5 million for an MD Anderson program that promotes physical activity for cancer survivors.
  • Almost $500,000 for an MD Anderson program to increase treatment of tobacco users who are participating in opioid treatment programs.
  • Nearly $500,000 for a University of Houston program designed to help LGBTQ+ Texans lead tobacco-free lives.

“From new research programs, recruitment of preeminent scientists to Texas, pilot studies, new technology, and expanding the reach of successful cancer prevention programs, [the] grants highlight the effect CPRIT is having on not just cancer research and prevention efforts, but on life science infrastructure in Texas,” Wayne Roberts, the organization’s CEO, said in a news release.

These cancer research professionals just got fresh funding from a statewide organization. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Texas nonprofit cancer research funder doles out millions to health professionals moving to Houston

money moves

Thanks in part to multimillion-dollar grants from the Cancer Prevention and Research Institute of Texas, two top-flight cancer researchers are taking key positions at Houston’s Baylor College of Medicine.

Dr. Pavan Reddy and Dr. Michael Taylor each recently received a grant of $6 million from the Cancer Prevention and Research Institute of Texas (CPRIT).

Reddy is leaving his position as chief of hematology-oncology and deputy director at the University of Michigan’s Rogel Cancer Center to become director of the Baylor College of Medicine’s Dan L. Duncan Comprehensive Cancer Center. Dr. C. Kent Osborne stepped down as the center’s director in 2020; Dr. Helen Heslop has been the interim director.

Taylor, a pediatric neurosurgeon at the University of Toronto, is set to become the first-ever director of pediatric neuro-oncology research at Texas Children’s Hospital. The hospital is affiliated with the Baylor College of Medicine. Taylor is an expert in children’s brain tumors.

In all, 11 researchers recruited by three health care institutions in Houston recently received $34 million in CPRIT grants. The nine other grant recipients in Houston are:

  • Dr. Christine Lovly, M.D. Anderson Cancer Center, $4 million. She is co-leader of the Translational Research and Interventional Oncology Research Program at the Vanderbilt-Ingram Cancer Center in Nashville.
  • Hans Renata, Rice University, $4 million. He is an associate professor at UF Scripps Biomedical Research in Jupiter, Florida.
  • Mingjie Dai, Rice University, $2 million. He is a technology development fellow at Harvard University’s Weiss Institute for Biologically Inspired Engineering.
  • William Hudson, Baylor College of Medicine, $2 million. He is a postdoctoral fellow at Emory University in Atlanta.
  • Deepshika Ramanan, M.D. Anderson Cancer Center, $2 million. She is a research fellow in immunology at Harvard Medical School.
  • Jason Schenkel, M.D. Anderson Cancer Center, $2 million. He is an instructor in pathology at Harvard’s Brigham and Women’s Hospital.
  • Aria Vaishnavi, M.D. Anderson Cancer Center, $2 million. She is a postdoctoral scholar at the University of Utah’s Huntsman Cancer Institute.
  • Samantha Yruegas, Rice University, $2 million. She is a postdoctoral research associate at Princeton University in New Jersey.
  • Qian Zhu, Baylor College of Medicine, $2 million. He is a research fellow at Harvard’s Dana-Farber Cancer Institute.

A CPRIT committee recently approved 17 recruitment grants totaling nearly $48 million for cancer research institutions in Texas.

“CPRIT’s mission is to invest in the research prowess of Texas institutions while expediting breakthroughs in cancer cures and prevention … . These 17 highly respected researchers will join an impressive roster of cancer-fighters who call the Lone Star State home,” says Wayne Roberts, CEO of CPRIT.

Since its creation, CPRIT has awarded $2.9 billion in grants to cancer research organizations around the state.

A UH researcher has fresh funding to support her life-saving, cancer-fighting drug. Photo via UH.edu

University of Houston researcher receives grant for first-of-its-kind breast cancer drug

funds granted

A University of Houston researcher was awarded a $2 million grant from the Cancer Prevention and Research Institute of Texas to develop a new drug that will initially target breast cancer, the university announced this month.

The drug is intended to impact a type of traditionally "undraggable" target of cancer, known as intrinsically disordered proteins (IDPs), which researchers have yet to gain fundamental understanding of. According to the release, approximately 70 percent of proteins impacted by cancer are considered IDPs.

Gül Zerze, an assistant professor in the William A. Brookshire Department of Chemical and Biomolecular Engineering at the UH Cullen College of Engineering, has specialized in research on the computational modeling and simulations of these IDPs, and is one of the 12 cancer researchers awarded such a grant by the CPRIT.

Candidates for Zerze's drug will be rapidly tested through collaborations within UH and MD Anderson, according to the statement.

Gül Zerze is an assistant professor in the William A. Brookshire Department of Chemical and Biomolecular Engineering. Photo via UH.edu

"One out of nearly six Texas women diagnosed with breast cancer will die of the disease. Importantly, Texan women of color are disproportionately impacted by the high mortality rate compared to white Texan women (41 percent higher mortality rate reported for Black Texan women in 2016)," Zerze said in a statement. "This high mortality rate, despite the substantial efforts made for early diagnosis, calls for better therapeutics urgently.”

Zerze was recruited by the CPRIT to come to UH from Princeton last November. She was part of the latest class of recruitment grants from the organization, totaling $38 million to “form a critical ecosystem of distinguished cancer-fighting talent” in Texas.

According to the CPRIT website, the organization has recruited 263 cancer researchers and their labs to Texas over the years. First launched in 2007, the CPRIT is now a $6 billion, 20-year initiative that's allowing institutions in Houston compete against the likes of Harvard and Stanford universities, and the Cleveland and Mayo clinics.

“The ideas proposed here will save lives," Zerze said in the statement. "And the products that will come out of this project have a great potential for commercialization and founding companies to contribute to the Texas economy.”

Allterum Therapeutics Inc., a portfolio company of Fannin Innovation Studio, is using the funds to prepare for clinical trials. Photo via Getty Images

Houston biotech startup raises millions to battle pediatric cancer

fresh funds

Allterum Therapeutics Inc. has built a healthy launchpad for clinical trials of an immunotherapy being developed to fight a rare form of pediatric cancer.

The Houston startup recently collected $1.8 million in seed funding through an investor group associated with Houston-based Fannin Innovation Studio, which focuses on commercializing biotech and medtech discoveries. Allterum has also brought aboard pediatric oncologist Dr. Philip Breitfeld as its chief medical officer. And the startup, a Fannin spinout, has received a $2.9 million grant from the Cancer Prevention Research Institute of Texas.

The funding and Breitfeld's expertise will help Allterum prepare for clinical trials of 4A10, a monoclonal antibody therapy for treatment of cancers that "express" the interleukin-7 receptor (IL7R) gene. These cancers include pediatric acute lymphoblastic leukemia (ALL) and some solid-tumor diseases. The U.S. Food and Drug Administration (FDA) has granted "orphan drug" and "rare pediatric disease" designations to Allterum's monoclonal antibody therapy.

If the phrase "monoclonal antibody therapy" sounds familiar, that's because the FDA has authorized emergency use of this therapy for treatment of COVID-19. In early January, the National Institute of Allergy and Infectious Diseases announced the start of a large-scale clinical trial to evaluate monoclonal antibody therapy for treatment of mild and moderate cases of COVID-19.

Fannin Innovation Studio holds exclusive licensing for Allterum's antibody therapy, developed at the National Cancer Institute. Aside from the cancer institute, Allterum's partners in advancing this technology include the Therapeutic Alliance for Children's Leukemia, Baylor College of Medicine, Texas Children's Hospital, Children's Oncology Group, and Leukemia & Lymphoma Society.

Although many pediatric patients with ALL respond well to standard chemotherapy, some patients continue to grapple with the disease. In particular, patients whose T-cell ALL has returned don't have effective standard therapies available to them. Similarly, patients with one type of B-cell ALL may not benefit from current therapies. Allterum's antibody therapy is designed to effectively treat those patients.

Later this year, Allterum plans to seek FDA approval to proceed with concurrent first- and second-phase clinical trials for its immunotherapy, says Dr. Atul Varadhachary, managing partner of Fannin Innovation Studio, and president and CEO of Allterum. The cash Allterum has on hand now will go toward pretrial work. That will include the manufacturing of the antibody therapy by Japan's Fujifilm Diosynth Biotechnologies, which operates a facility in College Station.

"The process of making a monoclonal antibody ready to give to patients is actually quite expensive," says Varadhachary, adding that Allterum will need to raise more money to carry out the clinical trials.

The global market for monoclonal antibody therapies is projected to exceed $350 billion by 2027, Fortune Business Insight says. The continued growth of these products "is expected to be a major driver of overall biopharmaceutical product sales," according to a review published last year in the Journal of Biomedical Science.

One benefit of these antibody therapies, delivered through IV-delivered infusions, is that they tend to cause fewer side effects than chemotherapy drugs, the American Cancer Society says.

"Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cancer cells. They are designed to bind to antigens that are generally more numerous on the surface of cancer cells than healthy cells," the Mayo Clinic says.

Varadhachary says that unlike chemotherapy, monoclonal antibody therapy takes aim at specific targets. Therefore, monoclonal antibody therapy typically doesn't broadly harm healthy cells the way chemotherapy does.

Allterum's clinical trials initially will involve children with ALL, he says, but eventually will pivot to children and adults with other kinds of cancer. Varadhachary believes the initial trials may be the first cancer therapy trials to ever start with children.

"Our collaborators are excited about that because, more often than not, the cancer drugs for children are ones that were first developed for adults and then you extend them to children," he says. "We're quite pleased to be able to do something that's going to be important to children."

Three health and tech research projects coming out of the Houston area have received grants to continue their work. Getty Images

These 3 Houston-area researchers receive millions in grants for ongoing innovation projects

Research roundup

Money makes the world go 'round, and that's certainly the case with research projects. Grants are what drives research at academic institutions across the country and fuel the next great innovations.

These three projects coming out of Houston-area universities were all granted multimillion-dollar sums in order to continue their health tech, cancer-prevention, and even electric vehicle battery research projects,

University of Houston's $3.2 million grant for its next-generation micro CT scan

Associate professor of physics Mini Das developed a better way to approach CT scans. Photo via uh.edu

In an effort to improve imaging and lower radiation, Mini Das, associate professor of physics at the University of Houston, is moving the needle on introducing the next generation of micro computed tomography (CT) imaging. Das recently received a five-year, $3.2 million grant from the National Institute of Biomedical Imaging and Bioengineering to help move along her work in this field.

"This has the potential to transform the landscape of micro-CT imaging," says Das in a news release.

Das is responsible for developing the theory, instrumentation and algorithms for spectral phase-contrast imaging (PCI) that allows for lower radiation with higher image details, according to the release.

"Current X-ray and CT systems have inherent contrast limitations and dense tissue and cancer can often look similar. Even if you increase the radiation dose, there is a limit to what you can see. In addition, image noise becomes significant when increasing resolution to see fine details, often desirable when scanning small objects," says Das.

Rice University researcher's $2.4 million grant to advance on car batteries

This company’s machine learning programs are making driving in Houston safer — and cheaper

A Rice University scientist is looking to optimize car batteries. Pexels

A Rice University scientist is working toward improving batteries for electric vehicles. Materials scientist Ming Tang and his colleagues — backed by a $2.4 million grant from the United States Advanced Battery Consortium — are working on a project led by Worcester Polytechnic Institute (WPI) in Massachusetts, which will run for 36 months and will focus on low-cost and fast-charging batteries.

"Traditional battery electrodes are prepared by the slurry casting method and usually have uniform porosity throughout the electrode thickness," says Tang, an assistant professor of materials science and nanoengineering, in a news release. "However, our earlier modeling study shows that an electrode could have better rate performance by having two or more layers with different porosities.

"Now with the Missouri University of Science and Technology and WPI developing a new dry printing method for battery electrode fabrication, such layered electrodes can be manufactured relatively easily," he said. Tang's group will use modeling to optimize the structural parameters of multilayer electrodes to guide their fabrication.

The academics will also work with a manufacturer, Microvast, that will assemble large-format pouch cells using layered electrodes and evaluate the electrochemical performance against the program goals, according to the release.

"The public/private partnership is critical to steer the research performed at universities," Tang says. "It helps us understand what matters most to commercial applications and what gaps remain between what we have and what is needed by the market. It also provides valuable feedback and gives the project access to the state-of-the-art commercial battery fabrication and testing capabilities."


Texas A&M faculty member's $5 million grant for cancer research

Tanmay Lele of Texas A&M University is looking at how cells react to mechanical forces in cancer. Photo via tamu.edu

Tanmay Lele, a new faculty member in Texas A&M University's Department of Biomedical Engineering, received a $5 million Recruitment of Established Investigators grant from the Cancer Prevention and Research Institute of Texas (CPRIT) in May to research how cancer progresses.

More specifically, Lele's research focuses on mechanobiology and how cells sense external mechanical forces as well as how they generate mechanical forces, and how these mechanical forces impact cell function, according to a news release from A&M.

"The nuclei in normal tissue have smooth surfaces, but over time the surfaces of cancer nuclei become irregular in shape," Lele says in the release. "Now, why? Nobody really knows. We're still at the tip of the iceberg at trying to figure this problem out. But nuclear abnormalities are ubiquitous and occur in all kinds of cancers — breast, prostate and lung cancers."

Lele will work from two laboratories — one in College Station and one in the Texas A&M Health Science Center's Institute of Biosciences & Technology in Houston. THe will collaborate with Dr. Michael Mancini and Dr. Fabio Stossi from Baylor College of Medicine.

"Like any other basic field, we are trying to make discoveries with the hope that they will have long-term impacts on human health," Lele says.

Five Houston research centers have received funds from the Cancer Prevention and Research Institute of Texas in its most recent round of grants. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Houston cancer-fighting researchers granted over $30 million from statewide organization

just granted

The Cancer Prevention and Research Institute of Texas has again granted millions to Texas institutions. Across the state, cancer-fighting scientists have received 55 new grants totaling over $78 million.

Five Houston-area institutions — Baylor College of Medicine, the University of Houston, The University of Texas Medical Branch at Galveston, The University of Texas Health Science Center at Houston, and the The University of Texas MD Anderson Cancer Center — have received around $30 million of that grand total.

"These awards reflect CPRIT's established priorities to invest in childhood cancer research, address population and geographic disparities, and recruit top cancer research talent to our academic institutions," says Wayne Roberts, CPRIT CEO, in a news release. "I'm excited about all the awardees, particularly those in San Antonio, a region that continues expand their cancer research and prevention prowess. San Antonio is poised to have an even greater impact across the Texas cancer-fighting ecosystem."

Four grants went to new companies that are bringing new technologies to the market. Two companies with a presence in Houston — Asylia Therapeutics and Barricade Therapeutics Corp. — received grants in this category.

Last fall, CPRIT gave out nearly $136 million to Texas researchers, and, to date, the organization has granted $2.49 billion to Texas research institutions and organizations.

Here's what recent grants were made to Houston institutions.

Baylor College of Medicine

  • $900,000 granted for Feng Yang's research in targeting AKT signaling in MAPK4-high Triple Negative Breast Cancer (Individual Investigator Award)
  • $897,527 Hyun-Sung Lee's research for Spatial Profiling of Tumor-Immune Microenvironment by Multiplexed Single Cell Imaging Mass Cytometry (Individual Investigator Award)
  • $899,847 for Joshua Wythe's research in targeting Endothelial Transcriptional Networks in GBM (Individual Investigator Award)

University of Houston

  • $890,502 for Matthew Gallagher's research in Transdiagnostic Cognitive Behavioral Therapy for Smokers With Anxiety and Depression (Individual Investigator Research Award for Prevention and Early Detection)
  • $299,953 for Lorraine Reitzel's research in Taking Texas Tobacco Free Through a Sustainable Education/Training Program Designed for Personnel Addressing Tobacco Control in Behavioral Health Settings (Dissemination of CPRIT-Funded Cancer Control Interventions Award)

The University of Texas Medical Branch at Galveston

  • $1,993,096 for Abbey Berenson's research in maximizing opportunities for HPV vaccination in medically underserved counties of Southeast Texas (Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations)

The University of Texas Health Science Center at Houston

  • $900,000 for Melissa Aldrich's research on "Can Microsurgeries Cure Lymphedema? An Objective Assessment" (Individual Investigator Award)
  • $900,000 for John Hancock's research in KRAS Spatiotemporal Dynamics: Novel Therapeutic Targets (Individual Investigator Award)
  • $900,000 for Nami McCarty's research in targeting Multiple Myeloma Stem Cell Niche (Individual Investigator Award)
  • $1.96 million for Paula Cuccaro's research in Expanding "All for Them": A comprehensive school-based approach to increase HPV vaccination through public schools (Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations)

The University of Texas MD Anderson Cancer Center

  • $900,000 for Laurence Court's research in Artificial Intelligence for the Peer Review of Radiation Therapy Treatments
  • $900,000 for John deGroot's research in targeting MEK in EGFR-Amplified Glioblastoma (Individual Investigator Award)
  • $900,000 for Don Gibbons's research in Investigating the Role ofCD38 as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer (Individual Investigator Award)
  • $900,000 for John Heymach's research in Molecular Features Impacting Drug Resistance in Atypical EGFR Exon 18 and Exon 20 Mutant NSCLC and the Development of Novel Mutant- Selective Inhibitors (Individual Investigator Award)
  • $900,000 for Zhen Fan's research in Development of a Novel Strategy for Tumor Delivery of MHC-I-Compatible Peptides for Cancer Immunotherapy (Individual Investigator Award)
  • $900,000 for Jin Seon Im's research in off the shelf, Cord-Derived iNK T cells Engineered to Prevent GVHD and Relapse After Hematopoietic Stem Cell Transplantation (Individual Investigator Award)
  • $900,000 for Jae-il Park's research in CRAD Tumor Suppressor and Mucinous Adenocarcinoma (Individual Investigator Award)
  • $900,000 for Helen Piwnica-Worms's research in Single-Cell Evaluation to Identify Tumor-stroma Niches Driving the Transition from In Situ to Invasive Breast Cancer (Individual Investigator Award)
  • $898,872 for Kunal Rai's research in Heterogeneity of Enhancer Patterns in Colorectal Cancers- Mechanisms and Therapy (Individual Investigator Award)
  • $900,000 for Ferdinandos Skoulidis's research in Elucidating Aberrant Splicing-Induced Immune Pathway Activation in RBMl0-Deficient KRAS-Mutant NSCLC and Harnessing Its Potential for Precision Immunotherapy (Individual Investigator Award)
  • $887,713 for Konstantin Sokolov's research in High-Sensitivity 19F MRI for Clinically Translatable Imaging of Adoptive NK Cell Brain Tumor Therapy (Individual Investigator Award)
  • $900,000 for Liuqing Yang's research in Adipocyte-Producing Noncoding RNA Promotes Liver Cancer Immunoresistance (Individual Investigator Award)
  • $1.44 million for Eugenie Kleinerman's research in Doxorubicin-Induced Cardiotoxicity: Defining Blood and Echocardiogram Biomarkers in a Mouse Model and AYA Sarcoma Patients for Evaluating Exercise Interventions (Individual Investigator Award for Cancer in Children and Adolescents)
  • $2.4 million for Arvind Dasari's research in Circulating Tumor DNA- Defined Minimal Residual Disease in Colorectal Cancer (Individual Investigator Research Award for Clinical Translation)
  • Targeting Alterations of the NOTCH! Pathway in Head and Neck Squamous Cell Carcinoma (HNSCC)(Faye Johnson) - $1.2 million (Individual Investigator Research Award for Clinical Translation)
  • $2.07 million for Florencia McAllister's research in Modulating the Gut- Tumor Microbial Axis to Reverse Pancreatic Cancer Immunosuooression (Individual Investigator Research Award for Clinical Translation)
  • $2 million to recruit Eric Smith, MD, PhD, to The University of Texas MD Anderson Cancer Center from Memorial Sloan Kettering Cancer Center (Recruitment of First-Time, Tenure-Track Faculty Members Award)
  • $2 million for Karen Basen-Engquist's research in Active Living After Cancer: Combining a Physical Activity Program with Survivor Navigation (Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations)


Seed Awards for Product Development Research

  • Houston and Boston-based Asylia Therapeutics's Jeno Gyuris was granted $3 million for its development of a Novel Approach to Cancer Immunotherapy by Targeting Extracellular Tumor- derived HSP70 to Dendritic Cells
  • Houston-based Barricade Therapeutics Corp.'s Neil Thapar was granted $3 million for its development of a First-In-Class Small Molecule, TASIN, for Targeting Truncated APC Mutations for the Treatment of Colorectal Cancer (CRC)
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston hailed as one of America's 10 best cities for startups

Startup Report

Houston's favorable economic climate is enticing new opportunities for entrepreneurship and growth, and now the city is being hailed as the 7th-best U.S. city for starting a business.

The recognition comes in CommercialCafe's recent "Best Cities for Startups" report, published December 10. The study analyzed large U.S. cities across two population categories – cities with more than 1 million residents and cities with populations between 500,000 and 1 million residents. The report analyzed relevant metrics such as office or coworking costs, Kickstarter funding success, startup density, and survival rates, among others.

Across the biggest U.S. cities with over a million residents, Phoenix, Arizona landed on top as the No. 1 best place to start a new business.

The report's findings revealed 10.6 percent of all businesses in Houston are startups that have been active for less than a year. These new businesses have a survival rate of 64.5 percent, meaning just under two-thirds of all startups in the city will still be running up to five years after they were first established.

Over the last five years, the number of new businesses established in Houston has grown nearly 15 percent. CommercialCafe said new businesses in cities with high startup growth rates tend to "attract top talent" which can eventually lead to securing "vital funding for expansion."

Independent professionals – also known as freelancers – are another crucial resource for new businesses that may need "specialized services" for a fixed amount of time, the report said. Houston's freelance workforce has grown about 9 percent from 2019-2023, and the analysis found there were 97,295 freelancers working in Houston in 2023, compared to 89,528 in 2019.

"Generally, cities in the South and Southwest have experienced strong growth during the surveyed period, in contrast to California cities like Los Angeles and San Diego, where the share of freelancers and gig workers has either stagnated or slightly declined," the report said.

Houston boasts the second-cheapest office space rent nationally, the report found. The average asking price for a 1,000-square-foot workspace (for five employees) in the city added up to $27,124 annually. For startups that want greater flexibility for their workers, the annual cost for a coworking space for the same number of employees in Houston came out to $13,200, which is the fourth-most affordable rate in the U.S.

Other Texas cities with attractive economic environments for startups

Texas, as a whole, is one of the strongest states for starting a new business. Other than Houston, San Antonio (No. 2), Dallas (No. 3), and Fort Worth (No. 4) were also recognized among the top 10 best places to start a business in the category of U.S. cities with more than a million residents.

Austin topped a separate ranking of best cities to start a business with 500,000 to 1 million residents.

"Specifically, the Texas capital was the frontrunner for indicators that looked at the overall share of startups within the local economy, as well as growth rates in five years (2019 to 2023)," the report said. "On top of that, Austin also topped the rankings for its percentage of college-educated residents and its consulting firms, which provide vital support for burgeoning enterprises."

The top 10 best cities to start a new business are:

  • No. 1 – Phoenix, Arizona
  • No. 2 – San Antonio, Texas
  • No. 3 – Dallas, Texas
  • No. 4 – Fort Worth, Texas
  • No. 5 – Jacksonville, Florida
  • No. 6 – San Diego, California
  • No. 7 – Houston, Texas
  • No. 8 – Philadelphia, Pennsylvania
  • No. 9 – Chicago, Illinois
  • No. 10 – Los Angeles, California
---

This article originally appeared on CultureMap.com.

Top Houston space news of 2025 soars with NASA deals, lunar missions

Year in Review

Editor's note: As 2025 comes to a close, we're looking back at the stories that defined Houston innovation this year. The space tech sector soared with companies landing huge NASA contracts and furthering their lunar missions. Here are the 10 biggest Houston space tech stories of the year:

Houston native picked for 2025 class of NASA astronaut candidates

Houston native Anna Menon, posing below the first A in “NASA,” is one of 10 new NASA astronaut candidates. Photo courtesy NASA.

NASA has selected 10 new astronaut candidates, including one whose hometown is Houston, for its 2025 training class. The candidates will undergo nearly two years of training before they can assume flight assignments.

Intuitive Machines lands $9.8M to complete orbital transfer vehicle

Intuitive Machines expects to begin manufacturing and flight integration on its orbital transfer vehicle as soon as 2026. Photo courtesy Intuitive Machines.

Houston-based Intuitive Machines, which rang the NASDAQ opening bell July 31, secured a $9.8 million Phase Two government contract for its orbital transfer vehicle. The contract will push the project through its Critical Design Review phase, which is the final engineering milestone before manufacturing can begin.

Houston tech company tapped by NASA for near space initiative

Intuitive Machines is among four companies awarded contracts for NASA’s Near Space Network. Photo via intuitivemachines.com

In January, Intuitive Machines nailed down a NASA deal to expand the agency’s communications network for spacecraft. Additionally, NASA completed the first round of “human in the loop” testing for Intuitive Machines’ Moon RACER lunar terrain vehicle at the agency’s Johnson Space Center. RACER (Reusable Autonomous Crewed Exploration Rover) is one of three commercially developed unpressurized lunar terrain vehicles being considered for NASA’s Artemis lunar initiative.

Texas Space Commission doles out $5.8 million to Houston companies

Axiom Space and FluxWorks are the latest Houston-area companies to receive funding from the Texas Space Commission. Photo via Getty Images.

Two Houston-area companies landed more than $5.8 million in funding from the Texas Space Commission. The commission granted up to $5.5 million to Houston-based Axiom Space and up to $347,196 to Conroe-based FluxWorks in June 2025. The two-year-old commission previously awarded $95.3 million to 14 projects. A little over $34 million remains in the commission-managed Space Exploration and Aeronautics Research Fund.

Houston company awarded $2.5B NASA contract to support astronaut health and space missions

NASA has awarded KBR a five-year, $2.5 billion Human Health and Performance Contract. Photo courtesy NASA.

Houston-based technology and energy solution company KBR was awarded a $2.5 billion NASA contract to support astronaut health and reduce risks during spaceflight missions. Under the terms of the Human Health and Performance Contract 2, KBR will provide support services for several programs, including the Human Research Program, International Space Station Program, Commercial Crew Program, Artemis campaign and others. This will include ensuring crew health, safety, and performance; occupational health services and risk mitigation research for future flights.

Houston engineering firm lands $400M NASA contract

Bastion Technologies has been tapped to provide safety and mission services for NASA's Marshall Space Flight Center in Alabama. Photo via nasa.gov.

NASA granted Houston-based Bastion Technologies Inc. the Safety and Mission Assurance II (SMAS II) award with a maximum potential value of $400 million. The award stipulates that the engineering and technical services company provide safety and mission services for the agency’s Marshall Space Flight Center in Huntsville, Alabama.

Houston startups win NASA funding for space tech projects

Houston startups were recently named among the nearly 300 recipients that received a portion of $44.85 million from NASA to develop space technology. Photo via NASA/Ben Smegelsky

Three Houston startups were granted awards from NASA in July 2025 to develop new technologies for the space agency. The companies were among nearly 300 recipients that received a total agency investment of $44.85 million through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase I grant programs.

Texas Republicans are pushing to move NASA headquarters to Houston

Here's why Texas Republicans think NASA's headquarters should move to Texas in 2028. File photo.

Two federal lawmakers from Texas spearheaded a campaign to relocate NASA’s headquarters from Washington, D.C., to the Johnson Space Center in Houston’s Clear Lake area. Houston faces competition on this front, though, as lawmakers from two other states are also vying for this NASA prize. With NASA’s headquarters lease in D.C. set to end in 2028, U.S. Sen. Ted Cruz, a Texas Republican, and U.S. Rep. Brian Babin, a Republican whose congressional district includes the Johnson Space Center, wrote a letter to President Trump touting the Houston area as a prime location for NASA’s headquarters.

Intuitive Machines to acquire NASA-certified deep space navigation company

Intuitive Machines will acquire Kinetx, which marks its entry into the precision navigation and flight dynamics segment of deep space operations. Photo via Getty Images.

In August 2025, Intuitive Machines agreed to buy Tempe, Arizona-based aerospace company KinetX for an undisclosed amount. The deal is expected to close by the end of this year. KinetX specializes in deep space navigation, systems engineering, ground software and constellation mission design. It’s the only company certified by NASA for deep space navigation. KinetX’s navigation software has supported both of Intuitive Machines’ lunar missions.

Axiom Space launches semiconductor and astronaut training initiatives

Axiom Space chief astronaut Michael López-Alegría (left) trains with Axiom’s new “Project Astronaut,” Emiliano Ventura. Photo courtesy of Axiom Space.

In fall 2025, Axiom Space, a Houston-based commercial spaceflight and space infrastructure company, launched initiatives in two very different spheres — semiconductors and astronaut training.

Paraplegic engineer becomes first wheelchair user to blast into space

Space News

A paraplegic engineer from Germany blasted off on a dream-come-true rocket ride with five other passengers Saturday, December 20, leaving her wheelchair behind to float in space while beholding Earth from on high.

Severely injured in a mountain bike accident seven years ago, Michaela Benthaus became the first wheelchair user in space, launching from West Texas with Jeff Bezos’ company Blue Origin. She was accompanied by a retired SpaceX executive also born in Germany, Hans Koenigsmann, who helped organize and, along with Blue Origin, sponsored her trip. Their ticket prices were not divulged.

An ecstatic Benthaus said she laughed all the way up — the capsule soared more than 65 miles (105 kilometers) — and tried to turn upside down once in space.

“It was the coolest experience,” she said shortly after landing.

The 10-minute space-skimming flight required only minor adjustments to accommodate Benthaus, according to the company. That’s because the autonomous New Shepard capsule was designed with accessibility in mind, “making it more accessible to a wider range of people than traditional spaceflight,” said Blue Origin’s Jake Mills, an engineer who trained the crew and assisted them on launch day.

Among Blue Origin’s previous space tourists: those with limited mobility and impaired sight or hearing, and a pair of 90-year-olds.

For Benthaus, Blue Origin added a patient transfer board so she could scoot between the capsule’s hatch and her seat. The recovery team also unrolled a carpet on the desert floor following touchdown, providing immediate access to her wheelchair, which she left behind at liftoff. She practiced in advance, with Koenigsmann taking part with the design and testing. An elevator was already in place at the launch pad to ascend the seven stories to the capsule perched atop the rocket.

Benthaus, 33, part of the European Space Agency’s graduate trainee program in the Netherlands, experienced snippets of weightlessness during a parabolic airplane flight out of Houston in 2022. Less than two years later, she took part in a two-week simulated space mission in Poland.

“I never really thought that going on a spaceflight would be a real option for me because even as like a super healthy person, it’s like so competitive, right?” she told The Associated Press ahead of the flight.

Her accident dashed whatever hope she had. “There is like no history of people with disabilities flying to space," she said.

When Koenigsmann approached her last year about the possibility of flying on Blue Origin and experiencing more than three minutes of weightlessness on a space hop, Benthaus thought there might be a misunderstanding. But there wasn't, and she immediately signed on.

It’s a private mission for Benthaus with no involvement by ESA, which this year cleared reserve astronaut John McFall, an amputee, for a future flight to the International Space Station. The former British Paralympian lost his right leg in a motorcycle accident when he was a teenager.

An injured spinal cord means Benthaus can’t walk at all, unlike McFall who uses a prosthetic leg and could evacuate a space capsule in an emergency at touchdown by himself. Koenigsmann was designated before flight as her emergency helper; he and Mills lifted her out of the capsule and down the short flight of steps at flight’s end.

“You should never give up on your dreams, right?” Benthaus urged following touchdown.

Benthaus was adamant about doing as much as she could by herself. Her goal is to make not only space accessible to the disabled, but to improve accessibility on Earth too.

While getting lots of positive feedback within “my space bubble,” she said outsiders aren't always as inclusive.

“I really hope it’s opening up for people like me, like I hope I’m only the start," she said.

Besides Koenigsmann, Benthaus shared the ride with business executives and investors, and a computer scientist. They raised Blue Origin’s list of space travelers to 86.

Bezos, the billionaire founder of Amazon, created Blue Origin in 2000 and launched on its first passenger spaceflight in 2021. The company has since delivered spacecraft to orbit from Cape Canaveral, Florida, using the bigger and more powerful New Glenn rocket, and is working to send landers to the moon.